Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)

Phase 2

Active, not recruiting

Conditions: Leukemia, Lymphoid
Lymphoma, Non-Hodgkin
Lymphoma, Mantle-Cell
Lymphoma, Large B-Cell, Diffuse
Lymphoma, B-Cell
Lymphoma, B-Cell, Marginal Zone
Leukemia, Lymphocytic, Chronic, B-Cell

Interventions: Drug: LOXO-305

First Posted Date: 2021-04-19

Last Posted Date: 2024-12-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 87

Registration Number: NCT04849416

Locations: 🇨🇳
Beijing Cancer hospital, Beijing, Beijing, China
🇨🇳
Hainan General Hospital, Haikou, Hainan, China
🇨🇳
Xingtai People's Hospital, Xingtai, Hebei, China

and more 19 locations

A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease

Phase 3

Completed

Conditions: Obesity

Interventions: Other: Placebo
Drug: Tirzepatide

First Posted Date: 2021-04-14

Last Posted Date: 2024-07-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 267

Registration Number: NCT04844918

Locations: 🇯🇵
Takatsuki Red Cross Hospital, Takatsuki, Osaka, Japan
🇯🇵
Saiseikai Matsuyama Hospital, Matsuyama, Ehime, Japan
🇯🇵
Motomachi Takatsuka Naika Clinic, Yokohama-city, Kanagawa, Japan

and more 15 locations

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

Phase 3

Recruiting

Conditions: Ulcerative Colitis
Ulcerative Colitis Chronic
Crohn's Disease
Inflammatory Bowel Diseases

Interventions: Drug: Mirikizumab

First Posted Date: 2021-04-14

Last Posted Date: 2024-12-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 150

Registration Number: NCT04844606

Locations: 🇮🇱
Yitzhak Shamir Medical Center, Zerifin, HaMerkaz, Israel
🇮🇱
Shaare Zedek Medical Center, Jerusalem, Yerushalayim, Israel
🇮🇹
AOU Policlinico Umberto I, Roma, Lazio, Italy

and more 45 locations

A Study of LY3484356 in Healthy Female Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3484356
Drug: Omeprazole
Drug: Itraconazole
Drug: Carbamazepine

First Posted Date: 2021-04-12

Last Posted Date: 2022-05-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 82

Registration Number: NCT04840888

Locations: 🇺🇸
LabCorp CRU, Inc., Daytona Beach, Florida, United States
🇺🇸
Covance Dallas, Dallas, Texas, United States

A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction

Phase 1

Completed

Conditions: Chronic Heart Failure With Reduced Ejection Fraction

Interventions: Drug: LY3461767
Drug: Placebo

First Posted Date: 2021-04-12

Last Posted Date: 2024-05-30

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 44

Registration Number: NCT04840914

Locations: 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇯🇵
Kanagawa Prefectural Hospital Organization Kanagawa Cardiovascular and Respiratory Center, Kanazawa Ward,Yokohama, Kanagawa, Japan
🇯🇵
National Cerebral and Cardiovascular Center, Suita-shi, Osaka, Japan

and more 4 locations

A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lebrikizumab

First Posted Date: 2021-04-12

Last Posted Date: 2024-11-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 242

Registration Number: NCT04840901

Locations: 🇺🇸
QPS, Springfield, Missouri, United States
🇺🇸
LabCorp CRU, Inc., Madison, Wisconsin, United States
🇺🇸
Covance Dallas, Dallas, Texas, United States

A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: LY3437943
Drug: Placebo

First Posted Date: 2021-03-30

Last Posted Date: 2022-08-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 64

Registration Number: NCT04823208

Locations: 🇯🇵
Clinical Research Hospital Tokyo, Shinjuku-ku, Tokyo, Japan
🇯🇵
Yokohama Minoru Clinic, Yokohama, Japan
🇯🇵
Medical Corporation Heishinkai OCROM Clinic, Suita-shi, Osaka, Japan

and more 1 locations

A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus
Diabetes Mellitus, Type 2
Endocrine System Diseases
Metabolic Disease
Type 2 Diabetes Mellitus (T2DM)
Glucose Metabolism Disorders
Hypoglycemic Agents

Interventions: Drug: Dulaglutide
Drug: Oral antihyperglycemics

First Posted Date: 2021-03-22

Last Posted Date: 2024-05-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 591

Registration Number: NCT04809220

Locations: 🇯🇵
Ota Diabetes Internal Medicine Clinic, Nagano, Japan
🇯🇵
Heiwadai Hospital, Miyazaki, Japan
🇯🇵
Hachioji Diabetes Clinic, Hachioji, Tokyo, Japan

and more 41 locations

A Study of LY3540378 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3540378
Drug: Placebo

First Posted Date: 2021-02-24

Last Posted Date: 2022-06-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 134

Registration Number: NCT04768855

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore

A Study of Two Different Formulations of LY3209590 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3209590

First Posted Date: 2021-02-24

Last Posted Date: 2021-09-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 50

Registration Number: NCT04768842

Locations: 🇬🇧
Covance Clinical Research, Leeds, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy